
David S Baldwin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8781005/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. World Journal of Biological Psychiatry, 2008, 9, 248-312.	1.3	661
2	Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2005, 19, 567-596.	2.0	537
3	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology, 2014, 28, 403-439.	2.0	511
4	Generalised anxiety disorder. Lancet, The, 2006, 368, 2156-2166.	6.3	265
5	Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ: British Medical Journal, 2011, 342, d1199-d1199.	2.4	236
6	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World Journal of Biological Psychiatry, 2017, 18, 162-214.	1.3	226
7	Paroxetine in social phobia/social anxiety disorder. British Journal of Psychiatry, 1999, 175, 120-126.	1.7	216
8	Escitalopram Therapy for Major Depression and Anxiety Disorders. Annals of Pharmacotherapy, 2007, 41, 1583-1592.	0.9	211
9	Benzodiazepines: Risks and benefits. A reconsideration. Journal of Psychopharmacology, 2013, 27, 967-971.	2.0	177
10	What Is the Threshold for Symptomatic Response and Remission for Major Depressive Disorder, Panic Disorder, Social Anxiety Disorder, and Generalized Anxiety Disorder?. Journal of Clinical Psychiatry, 2006, 67, 1428-1434.	1.1	177
11	Transcranial direct current stimulation (tDCS) in the treatment of depression: Systematic review and meta-analysis of efficacy and tolerability. Neuroscience and Biobehavioral Reviews, 2015, 57, 46-62.	2.9	175
12	British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. Journal of Psychopharmacology, 2017, 31, 519-552.	2.0	166
13	The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Journal of Psychopharmacology, 2016, 30, 242-252.	2.0	132
14	Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study. Brain, Behavior, and Immunity, 2017, 62, 212-218.	2.0	132
15	A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). European Neuropsychopharmacology, 2012, 22, 482-491.	0.3	130
16	Evidence-based pharmacological treatment of generalized anxiety disorder. International Journal of Neuropsychopharmacology, 2011, 14, 697-710.	1.0	125
17	Escitalopram and paroxetine in the treatment of generalised anxiety disorder. British Journal of Psychiatry, 2006, 189, 264-272.	1.7	124
18	The economic consequences of social phobia. Journal of Affective Disorders, 2002, 68, 221-233.	2.0	123

#	Article	IF	CITATIONS
19	Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics. World Journal of Biological Psychiatry, 2016, 17, 321-365.	1.3	118
20	The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry, 2018, 17, 3-11.	4.8	112
21	Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis. Brain, Behavior, and Immunity, 2019, 79, 24-38.	2.0	112
22	Which Factors Predict Placebo Response in Anxiety Disorders and Major Depression?. Journal of Clinical Psychiatry, 2006, 67, 1741-1746.	1.1	108
23	Evidence-based pharmacotherapy of Generalized Anxiety Disorder. International Journal of Neuropsychopharmacology, 2005, 8, 293-302.	1.0	105
24	Estimating the Prevalence and Impact of Antidepressant-Induced Sexual Dysfunction in 2 European Countries. Journal of Clinical Psychiatry, 2006, 67, 204-210.	1.1	102
25	Discontinuation symptoms in depression and anxiety disorders. International Journal of Neuropsychopharmacology, 2007, 10, 73.	1.0	97
26	The SSRIs: Advantages, disadvantages and differences. Journal of Psychopharmacology, 1995, 9, 163-178.	2.0	93
27	A neuroimmunological perspective on anxiety disorders. Human Psychopharmacology, 2012, 27, 6-14.	0.7	90
28	Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: A pooled analysis of 6 studies. European Neuropsychopharmacology, 2008, 18, 422-430.	0.3	81
29	The generalized anxiety spectrum: prevalence, onset, course and outcome. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 37-45.	1.8	81
30	A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. International Clinical Psychopharmacology, 2006, 21, 159-169.	0.9	80
31	Sexual dysfunction associated with antidepressant drugs. Expert Opinion on Drug Safety, 2004, 3, 457-470.	1.0	78
32	Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Human Psychopharmacology, 2010, 25, 17-29.	0.7	70
33	A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. Journal of Affective Disorders, 2016, 206, 140-150.	2.0	67
34	Role of dopamine in schizophrenia and Parkinson's disease. British Journal of Nursing, 1998, 7, 832-841.	0.3	65
35	Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatric Disease and Treatment, 2013, 9, 883.	1.0	65
36	Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. Psychopharmacology, 2004, 176, 466-470.	1.5	64

#	Article	IF	CITATIONS
37	A systematic review of the predictors of health service utilisation by adults with mental disorders in the UK. BMJ Open, 2015, 5, e007575.	0.8	62
38	Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. Journal of Psychopharmacology, 2006, 20, 91-96.	2.0	60
39	Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Current Medical Research and Opinion, 2012, 28, 1717-1724.	0.9	60
40	Placebo-controlled studies in depression: necessary, ethical and feasible. European Archives of Psychiatry and Clinical Neuroscience, 2003, 253, 22-28.	1.8	59
41	Antidepressant drugs and sexual dysfunction. British Journal of Psychiatry, 2013, 202, 396-397.	1.7	59
42	An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World Journal of Biological Psychiatry, 2012, 13, 510-516.	1.3	56
43	Research in anxiety disorders: From the bench to the bedside. European Neuropsychopharmacology, 2009, 19, 381-390.	0.3	53
44	Preferential Consolidation of Emotional Memory During Sleep: A Meta-Analysis. Frontiers in Psychology, 2019, 10, 1014.	1.1	52
45	How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Human Psychopharmacology, 2009, 24, 269-275.	0.7	51
46	Inhalation of 7.5% Carbon Dioxide Increases Threat Processing in Humans. Neuropsychopharmacology, 2011, 36, 1557-1562.	2.8	51
47	Electroencephalographic delta/alpha frequency activity differentiates psychotic disorders: a study of schizophrenia, bipolar disorder and methamphetamine-induced psychotic disorder. Translational Psychiatry, 2018, 8, 75.	2.4	51
48	Effects of antidepressant drugs on sexual function. International Journal of Psychiatry in Clinical Practice, 1997, 1, 47-58.	1.2	47
49	Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. Journal of Psychopharmacology, 2015, 29, 1047-1060.	2.0	47
50	A critical review of the definition of â€~wellbeing' for doctors and their patients in a post Covid-19 era. International Journal of Social Psychiatry, 2021, 67, 984-991.	1.6	47
51	Investigation of Cortisol Levels in Patients with Anxiety Disorders: A Structured Review. Current Topics in Behavioral Neurosciences, 2014, 18, 191-216.	0.8	46
52	Impact of Antidepressant Drugs on Sexual Function and Satisfaction. CNS Drugs, 2015, 29, 905-913.	2.7	44
53	Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder. Brain, Behavior, and Immunity, 2019, 81, 105-110.	2.0	44
54	Resilience as a predictor of treatment response in patients with posttraumatic stress disorder treated with venlafaxine extended release or placebo. Journal of Psychopharmacology, 2012, 26, 778-783.	2.0	43

#	Article	IF	CITATIONS
55	Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence. Drug Safety, 2016, 39, 627-645.	1.4	43
56	Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. International Clinical Psychopharmacology, 2012, 27, 197-207.	0.9	42
57	Pharmacology for sleep disturbance in PTSD. Human Psychopharmacology, 2016, 31, 156-163.	0.7	41
58	Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatric Disease and Treatment, 2007, 3, 185-191.	1.0	41
59	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 207-245.	1.8	40
60	Inhalation of 7.5% carbon dioxide increases alerting and orienting attention network function. Psychopharmacology, 2012, 223, 67-73.	1.5	40
61	Altered executive control network resting-state connectivity in social anxiety disorder. World Journal of Biological Psychiatry, 2016, 17, 47-57.	1.3	39
62	Clinically relevant drug interactions in anxiety disorders. Human Psychopharmacology, 2012, 27, 239-253.	0.7	36
63	Effects of age and gender on elderly suicide rates in Catholic and Orthodox countries: an inadvertent neglect?. International Journal of Geriatric Psychiatry, 2000, 15, 904-910.	1.3	33
64	Escitalopram in the treatment of generalized anxiety disorder. Expert Review of Neurotherapeutics, 2005, 5, 443-449.	1.4	33
65	Lithium and sexual dysfunction: an underâ€researched area. Human Psychopharmacology, 2015, 30, 66-69.	0.7	33
66	Obsessive-compulsive symptoms and the Covid-19 pandemic: A rapid scoping review. Neuroscience and Biobehavioral Reviews, 2022, 132, 1086-1098.	2.9	32
67	Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets. CNS Drugs, 2017, 31, 307-317.	2.7	31
68	The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management. World Psychiatry, 2021, 20, 336-356.	4.8	31
69	The separation of adult separation anxiety disorder. CNS Spectrums, 2016, 21, 289-294.	0.7	30
70	Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Human Psychopharmacology, 2008, 23, 527-532.	0.7	29
71	The relationships among separation anxiety disorder, adult attachment style and agoraphobia in patients with panic disorder. Journal of Anxiety Disorders, 2014, 28, 741-746.	1.5	29
72	The future of antidepressant pharmacotherapy. World Psychiatry, 2003, 2, 3-8.	4.8	28

#	Article	IF	CITATIONS
73	Psychotropic Drugs and Sexual Dysfunction. International Review of Psychiatry, 1995, 7, 261-273.	1.4	27
74	Antipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalized anxiety disorder. Journal of Psychopharmacology, 1998, 12, 323-329.	2.0	27
75	Off-label prescribing by psychiatrists. Psychiatric Bulletin, 2000, 24, 415-417.	0.3	26
76	Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders. International Journal of Psychiatry in Clinical Practice, 2006, 10, 12-15.	1.2	26
77	Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo. European Neuropsychopharmacology, 2016, 26, 1062-1069.	0.3	26
78	Symptoms of fatigue and sleepiness in major depressive disorder. Journal of Clinical Psychiatry, 2006, 67 Suppl 6, 9-15.	1.1	26
79	Pharmacological Treatment of Generalized Anxiety Disorder. Current Topics in Behavioral Neurosciences, 2009, 2, 453-467.	0.8	25
80	A 2010 Evidence-Based Algorithm for the Pharmacotherapy of Social Anxiety Disorder. Current Psychiatry Reports, 2010, 12, 471-477.	2.1	25
81	The Effect of Prefrontal Transcranial Direct Current Stimulation on Attention Network Function in Healthy Volunteers. Neuromodulation, 2018, 21, 355-361.	0.4	25
82	Optimal treatment for obsessive compulsive disorder. International Clinical Psychopharmacology, 2018, 33, 334-348.	0.9	25
83	Superiority of escitalopram to paroxetine in the treatment of depression. European Neuropsychopharmacology, 2009, 19, 229-237.	0.3	24
84	The Asian Cultural Identity Schedule: an investigation of culture and deliberate self-harm. International Journal of Methods in Psychiatric Research, 1999, 8, 212-218.	1.1	23
85	Treatment of Obsessive-Compulsive Disorder. CNS Spectrums, 2007, 12, 28-35.	0.7	23
86	Treatment with citalopram, but not with agomelatine, adversely affects sperm parameters: a case report and translational review. Acta Neuropsychiatrica, 2014, 26, 125-129.	1.0	23
87	Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive–compulsive disorder?. International Clinical Psychopharmacology, 2016, 31, 347-352.	0.9	23
88	Identity in recovery from problematic alcohol use: A qualitative study of online mutual aid. Drug and Alcohol Dependence, 2017, 174, 17-22.	1.6	23
89	Room for Improvement in the Pharmacological Treatment of Anxiety Disorders. Current Pharmaceutical Design, 2008, 14, 3482-3491.	0.9	22
90	Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants. Depression Research and Treatment, 2013, 2013, 1-8.	0.7	22

#	Article	IF	CITATIONS
91	Oxytocin receptor and G-protein polymorphisms in patients with depression and separation anxiety. Journal of Affective Disorders, 2017, 218, 365-373.	2.0	22
92	Manifesto for a European Anxiety Disorders Research Network. European Neuropsychopharmacology, 2010, 20, 426-432.	0.3	21
93	Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?. European Neuropsychopharmacology, 2012, 22, 137-142.	0.3	21
94	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 13-22.	1.8	21
95	Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review. Human Psychopharmacology, 2017, 32, e2628.	0.7	21
96	Efficacy of vortioxetine on the physical symptoms of major depressive disorder. Journal of Psychopharmacology, 2018, 32, 1086-1097.	2.0	21
97	Structured review of the use of the Arizona sexual experiences scale in clinical settings. Human Psychopharmacology, 2020, 35, e2730.	0.7	21
98	Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review. Health Technology Assessment, 2014, 18, 1-60.	1.3	20
99	Evaluating psychological interventions in a novel experimental human model of anxiety. Journal of Psychiatric Research, 2015, 63, 117-122.	1.5	20
100	Effects of repeated attachment security priming in outpatients with primary depressive disorders. Journal of Affective Disorders, 2018, 234, 201-206.	2.0	20
101	Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively. CNS Drugs, 2021, 35, 703-716.	2.7	19
102	Daytime intrusive thoughts and subjective insomnia symptoms. Psychiatry Research, 2015, 229, 1038-1042.	1.7	18
103	Covid-19: doctors must take control of their wellbeing. BMJ, The, 2020, 369, m1725.	3.0	18
104	Cost-Effectiveness Analysis of Escitalopram Compared with Paroxetine in Treatment of Generalized Anxiety Disorder in the United Kingdom. Annals of Pharmacotherapy, 2006, 40, 1752-1758.	0.9	17
105	Antidepressants, withdrawal, and addiction; where are we now?. Journal of Psychopharmacology, 2019, 33, 655-659.	2.0	17
106	The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2021, 125, 296-313.	2.9	17
107	A factor analysis of posttraumatic stress disorder symptoms using data pooled from two venlafaxine extendedâ€release clinical trials. Brain and Behavior, 2013, 3, 738-746.	1.0	16
108	Health literacy and the pharmacological treatment of anxiety disorders: a systematic review. Human Psychopharmacology, 2014, 29, 211-215.	0.7	16

#	Article	IF	CITATIONS
109	Systematic review of blood transcriptome profiling in neuropsychiatric disorders: guidelines for biomarker discovery. Human Psychopharmacology, 2016, 31, 373-381.	0.7	16
110	Clinical experience with paroxetine in social anxiety disorder. International Clinical Psychopharmacology, 2000, 15, S19-S24.	0.9	15
111	Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670. Journal of Psychopharmacology, 2008, 22, 55-63.	2.0	15
112	Can we distinguish anxiety from depression?. Psychopharmacology Bulletin, 2002, 36 Suppl 2, 158-65.	0.0	15
113	Unmet needs in the pharmacological management of depression. Human Psychopharmacology, 2001, 16, S93-S99.	0.7	14
114	A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. Journal of Psychopharmacology, 2001, 15, 161-165.	2.0	14
115	Escitalopram: efficacy and tolerability in the treatment of depression. British Journal of Hospital Medicine, 2002, 63, 668-671.	0.3	14
116	Manifesto for an international digital mental health network. Digital Psychiatry, 2019, 2, 14-24.	2.1	14
117	A neurobiological framework of separation anxiety and related phenotypes. European Neuropsychopharmacology, 2020, 33, 45-57.	0.3	14
118	Evidence-based Guidelines for Anxiety Disorders: Can They Improve Clinical Outcomes?. CNS Spectrums, 2006, 11, 34-39.	0.7	13
119	The Overlap of Obsessive-Compulsive Disorder and Social Phobia and its Treatment. CNS Spectrums, 2008, 13, 47-53.	0.7	13
120	Where is the room for improvement in the drug treatment of depression and anxiety?. Human Psychopharmacology, 2011, 26, 1-3.	0.7	13
121	Pharmacological Treatment of Panic Disorder. Modern Problems of Pharmacopsychiatry, 2013, 29, 128-143.	2.5	13
122	Prevalence, clinical correlates and IQ of suicidal ideation in drug naÃ⁻ve Chinese Han patients with major depressive disorder. Journal of Affective Disorders, 2019, 248, 59-64.	2.0	13
123	Effects of celecoxib augmentation of antidepressant or anxiolytic treatment on affective symptoms and inflammatory markers in patients with anxiety disorders: exploratory study. International Clinical Psychopharmacology, 2021, 36, 126-132.	0.9	13
124	Dysthymia. CNS Drugs, 1995, 4, 422-431.	2.7	12
125	Utility of the Health of the Nation Outcome Scales (HoNOS) in Predicting Mental Health Service Costs for Patients with Common Mental Health Problems: Historical Cohort Study. PLoS ONE, 2016, 11, e0167103.	1.1	12
126	Developing a European research network to address unmet needs in anxiety disorders. Neuroscience and Biobehavioral Reviews, 2013, 37, 2312-2317.	2.9	11

#	Article	IF	CITATIONS
127	Early effects of duloxetine on emotion recognition in healthy volunteers. Journal of Psychopharmacology, 2015, 29, 634-641.	2.0	11
128	Genetic mechanisms of electroconvulsive therapy response in depression. Human Psychopharmacology, 2016, 31, 247-251.	0.7	11
129	Cancer, Benign Gynecology, and Sexual Function—Issues and Answers. Journal of Sexual Medicine, 2016, 13, 519-537.	0.3	11
130	Why we need more research into the placebo response in psychiatry. Psychological Medicine, 2020, 50, 2317-2323.	2.7	10
131	Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential. American Journal of Psychiatry, 2019, 176, 966-966.	4.0	9
132	Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications. Addiction, 2022, 117, 1472-1482.	1.7	9
133	Yogic breathing instruction in patients with treatment-resistant generalized anxiety disorder: Pilot study. International Journal of Yoga, 2019, 12, 78.	0.4	9
134	Functional Neuroimaging Correlates of Placebo Response in Patients With Depressive or Anxiety Disorders: A Systematic Review. International Journal of Neuropsychopharmacology, 2022, 25, 433-447.	1.0	9
135	Anxiety symptom severity and functional recovery or relapse. Annals of Clinical Psychiatry, 2009, 21, 81-8.	0.6	9
136	Poor monitoring of physical health in patients referred to a mood disorders service. Therapeutic Advances in Psychopharmacology, 2015, 5, 22-25.	1.2	8
137	Sense and Sensibility When Prescribing â€~Off-Label' to Psychiatric Patients. Current Pharmaceutical Design, 2015, 21, 3276-3279.	0.9	8
138	On assessing potential efficacy for vortioxetine in generalized anxiety disorder. European Neuropsychopharmacology, 2012, 22, 841-843.	0.3	7
139	Should benzodiazepines still have a role in treating patients with anxiety disorders?. Human Psychopharmacology, 2012, 27, 237-238.	0.7	7
140	Altruism, personal benefit, and anxieties: a phenomenological study of healthy volunteers' experiences in a placebo-controlled trial of duloxetine. Human Psychopharmacology, 2016, 31, 332-340.	0.7	7
141	Attentional biases in patients with alcohol dependence: influence of coexisting psychopathology. Human Psychopharmacology, 2016, 31, 395-401.	0.7	7
142	Selective serotonin reuptake inhibitors in the treatment of generalized anxiety disorder. Expert Review of Neurotherapeutics, 2002, 2, 717-724.	1.4	6
143	Pharmacological treatment of social phobia. Psychiatry (Abingdon, England), 2007, 6, 217-223.	0.2	6
144	The Pharmacologic Treatment of Patients With Generalized Anxiety Disorder: Where Are We Now and Where Are We Going?. CNS Spectrums, 2009, 14, 5-12.	0.7	6

#	Article	IF	CITATIONS
145	A joint European and South African research network in anxiety disorders. Human Psychopharmacology, 2012, 27, 4-5.	0.7	6
146	Vortioxetine in the treatment of major depressive disorder. Future Neurology, 2015, 10, 79-89.	0.9	6
147	Prescription of Valproate-Containing Medicines in Women of Childbearing Potential who have Psychiatric Disorders: Is It Worth the Risk?. CNS Drugs, 2020, 34, 163-169.	2.7	6
148	Ruminations and their correlates in depressive episodes: Between-group comparison in patients with unipolar or bipolar depression and healthy controls. Journal of Affective Disorders, 2021, 280, 1-6.	2.0	6
149	Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness. Journal of Affective Disorders, 2022, 311, 588-594.	2.0	6
150	Cross-Sectional Associations of Depressive Symptom Severity and Functioning with Health Service Use by Older People in Low-and-Middle Income Countries. International Journal of Environmental Research and Public Health, 2015, 12, 3774-3792.	1.2	5
151	Pharmacological provocation and prevention of suicidal behaviour. International Review of Psychiatry, 2000, 12, 54-61.	1.4	4
152	On predicting the response to antidepressant treatment. Human Psychopharmacology, 2012, 27, 343-344.	0.7	4
153	Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression. International Clinical Psychopharmacology, 2014, 29, 339-343.	0.9	4
154	Hair cortisol concentration in anxiety disorders: exploration of relationships with symptom severity and inflammatory markers. Acta Neuropsychiatrica, 2021, 33, 104-110.	1.0	4
155	Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine. Frontiers in Psychiatry, 2021, 12, 784370.	1.3	4
156	Patient experience of lasting negative effects of psychological interventions for anxiety and depression in secondary mental health care services: a national cross-sectional study. BMC Psychiatry, 2021, 21, 578.	1.1	4
157	Feasibility and acceptability of transcranial stimulation in obsessive–compulsive symptoms (FEATSOCS): study protocol for a randomised controlled trial of transcranial direct current stimulation (tDCS) in obsessive–compulsive disorder (OCD). Pilot and Feasibility Studies, 2021, 7, 213.	0.5	4
158	Overcoming challenges in the management of schizophrenia. International Journal of Psychiatry in Clinical Practice, 1999, 3, 11-15.	1.2	3
159	The importance of long-term tolerability in achieving recovery. International Journal of Psychiatry in Clinical Practice, 2006, 10, 31-37.	1.2	3
160	Chapter 5.2 How effective are current drug treatments for anxiety disorders, and how could they be improved?. Handbook of Behavioral Neuroscience, 2008, , 395-411.	0.7	3
161	On reducing the duration of untreated illness in unipolar depression. Human Psychopharmacology, 2011, 26, 93-94.	0.7	3
162	Psychiatry should not become hostage to placebo: An alternative interpretation of antidepressant–placebo differences in the treatment response in depression. European Neuropsychopharmacology, 2012, 22, 782-786.	0.3	3

#	Article	IF	CITATIONS
163	Quality of case reports of adverse drug reactions with psychotropic drugs: a 25â€year review. Human Psychopharmacology, 2013, 28, 413-420.	0.7	3
164	Benzodiazepines: Risks and Benefits. A Reconsideration. Focus (American Psychiatric Publishing), 2014, 12, 229-234.	0.4	3
165	Adult separation anxiety disorder: accepted but little understood. Human Psychopharmacology, 2015, 30, 1-3.	0.7	3
166	Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry, the, 2019, 6, 560-561.	3.7	3
167	Brain Functional Connectivity Correlates of Response in the 7.5% CO2 Inhalational Model of Generalized Anxiety Disorder: A Pilot Study. International Journal of Neuropsychopharmacology, 2020, 23, 268-273.	1.0	3
168	Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532110023.	1.2	3
169	Diverse predictors of treatment response to active medication and placebo in gambling disorder. Journal of Psychiatric Research, 2021, 144, 96-101.	1.5	3
170	Course and outcome of patients with alcohol use disorders following an alcohol intervention during hospital attendance: mixed method study. BJPsych Open, 2021, 7, e6.	0.3	3
171	Short-term treatment with hypnotic drugs for insomnia: going beyond the evidence. Journal of Psychopharmacology, 2005, 19, 134-135.	2.0	2
172	Development and evaluation of psychotropic drugs. Psychiatry (Abingdon, England), 2007, 6, 279-283.	0.2	2
173	Agomelatine improves symptoms of generalised anxiety disorder. Evidence-Based Mental Health, 2009, 12, 54-54.	2.2	2
174	Neurotic, stress-related and somatoform disorders. , 2010, , 453-491.		2
175	Overcoming barriers in the pharmacological treatment of anxiety disorders. Neuropsychiatry, 2013, 3, 33-44.	0.4	2
176	Does previous experience of antidepressants form the expectations necessary for a placebo response?. British Journal of Psychiatry, 2015, 207, 561-561.	1.7	2
177	A personal account of depressive illness and its antidepressant treatment. International Clinical Psychopharmacology, 2019, 34, 286-290.	0.9	2
178	The validity of the state–trait anxiety inventory and the brief scale for anxiety in an inpatient sample with alcohol use disorder. Addiction, 2021, 116, 3055-3068.	1.7	2
179	What is mental wellbeing?. BJPsych Open, 2021, 7, S236-S236.	0.3	2
180	Time to Reconsider Monoamine Oxidase Inhibitors for Obsessive Compulsive Disorder? A Case Series Using Phenelzine. Journal of Clinical Psychopharmacology, 2021, Publish Ahead of Print, 461-464.	0.7	2

#	Article	IF	CITATIONS
181	Clinical evaluation of psychotropic drugs. Psychiatry (Abingdon, England), 2004, 3, 14-17.	0.2	1
182	Editorial. International Journal of Psychiatry in Clinical Practice, 2010, 14, 235-235.	1.2	1
183	Agomelatine in the treatment of mood and anxiety disorders. British Journal of Hospital Medicine (London, England: 2005), 2010, 71, 153-156.	0.2	1
184	Evidence-based pharmacotherapy of generalized anxiety disorder. , 0, , 110-127.		1
185	Antidepressants for insomnia. The Cochrane Library, 2013, , .	1.5	1
186	Can cognitive behaviour therapy beneficially influence arousal mechanisms in psychosis?. Human Psychopharmacology, 2016, 31, 64-69.	0.7	1
187	A personal account of reducing and stopping antidepressant treatment. International Clinical Psychopharmacology, 2020, Publish Ahead of Print, 194-200.	0.9	1
188	The effect of attachment security priming and oxytocin on physiological responses to trauma films and subsequent intrusions. Behaviour Research and Therapy, 2021, 141, 103845.	1.6	1
189	Mental wellbeing in doctors: the measure matters! development of a core outcome set for measuring wellbeing in doctors. BJPsych Open, 2021, 7, S235-S236.	0.3	1
190	Safety and Tolerability of Antidepressants. , 2016, , 149-166.		1
191	Antipsychotic drugs for non-psychotic patients. Psychiatric Bulletin, 1999, 23, 416-418.	0.3	1
192	The first patient to receive olanzapine: A recollection. Human Psychopharmacology, 2021, 36, e2823.	0.7	1
193	Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study. CNS Spectrums, 2023, 28, 46-52.	0.7	1
194	What medical students think about measurement of their well-being: cross-sectional survey and qualitative interviews. BMJ Open, 2022, 12, e056749.	0.8	1
195	Relationship of behavioral inhibition to separation anxiety in a sample (NÂ=Â377) of adult individuals with mood and anxiety disorders. Comprehensive Psychiatry, 2022, 116, 152326.	1.5	1
196	Threat reversal learning and avoidance habits in generalised anxiety disorder. Translational Psychiatry, 2022, 12, .	2.4	1
197	TRENDS IN CARDIOLOGY: CURRENT VIEWS ON THE ETIOLOGY AND TREATMENT OF HYPERTENSIONâ€. Journal of the American Geriatrics Society, 1964, 12, 239-244.	1.3	0
198	More scrutiny required: An audit of the distribution of The Royal College of Psychiatrists' â€~Help is at Hand' leaflet on social phobia. International Journal of Health Promotion and Education, 1999, 37, 19-21.	0.4	0

#	Article	IF	CITATIONS
199	SSRIs in the Treatment of Generalized Anxiety Disorder. , 2001, , 193-209.		0
200	Discharging psychiatric patients from hospital. Psychiatric Bulletin, 2002, 26, 436-436.	0.3	0
201	Off-label prescribing. Psychiatric Bulletin, 2002, 26, 394-394.	0.3	0
202	Anxiety disorders: does one treatment fit all?. International Journal of Psychiatry in Clinical Practice, 2004, 8, 31-35.	1.2	0
203	Psychotropic Drug Directory 2003/04. The Professionals' Pocket Handbook & Aide Memoire. Stephen Bazire. Salisbury: Fivepin Publishing, 2003, £24.99 pb, 416 pp, ISBN: 0 95 448839 01. Psychiatric Bulletin, 2005, 29, 239-239.	0.3	0
204	Depression and Personality: Conceptual and Clinical Challenges. Edited by Michael Rosenbluth, Sidney H. Kennedy & R. Michael Bagby. American Psychiatric Publishing. 2005. 338 pp. US\$39.95 (pb). ISBN 1585621544. British Journal of Psychiatry, 2007, 190, 541-542.	1.7	0
205	Suicide by veterinary surgeons. Veterinary Record, 2008, 162, 355-356.	0.2	0
206	Treatment of generalised anxiety and somatoform disorders. , 0, , 525-541.		0
207	Introduction to Neuropsychopharmacology By Leslie L. Iversen, Susan D. Iversen, Floyd E. Bloom and Robert H. Roth Oxford University Press. 2009. £30.00 (pb). 558pp. ISBN: 9780195380538. British Journal of Psychiatry, 2010, 196, 499-500.	1.7	0
208	Authors' Reply to Alain Braillon's Comment on "Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence― Drug Safety, 2016, 39, 1153-1154.	1.4	0
209	Experimental Medicine Models in Generalized Anxiety Disorder and Social Anxiety Disorder. Handbook of Behavioral Neuroscience, 2019, 29, 363-374.	0.7	0
210	Drugs to Treat Anxiety and Insomnia. , 2020, , 268-289.		0
211	Quality of English inpatient mental health services for people with anxiety or depressive disorders: Findings and recommendations from the core audit of the National Clinical Audit of Anxiety and Depression. Comprehensive Psychiatry, 2021, 104, 152212.	1.5	0
212	Capacity for cortical excitation is reduced in psychotic disorders: An investigation of the TMS-EMG cortical silent period. Schizophrenia Research, 2022, 240, 73-77.	1.1	0
213	Authors' Reply to Ulrich: Comment on †Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use Them Safely and Effectively'. CNS Drugs, 2022, 36, 103-103.	2.7	0